As of 2021 April 07, Wednesday current price of … 01:17 AM ET. Daily Stock Ratings Daily Insider Transactions. Pulmatrix does not have a long track record of dividend growth. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Frankfurt Stock Market & Finance report, prediction for the future: You'll find the Pulmatrix share forecasts, stock quote and buy / sell signals below.According to present data Pulmatrix's 2PU1 shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. 1 of the analysts rate the stock as a “Buy”. View Pulmatrix's (NASDAQ:PULM) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. ), Pulmatrix has received 141 “underperform” votes. The PE ratio stands at 0 for Pulmatrix, Inc., compared to 20.22 for Amgen Inc, and 0 for Bristol-Myers Squibb Company. Only 19.33% of the stock of Pulmatrix is held by institutions. Screeners. Find real-time PULM - Pulmatrix Inc stock quotes, company profile, news and forecasts from CNN Business. View the latest Pulmatrix Inc. (PULM) stock price, news, historical charts, analyst ratings and financial information from WSJ. To see all exchange delays and terms of use please see disclaimer. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 Wall Street analysts have given Pulmatrix a "Buy" rating, but there may be better short-term opportunities in the market. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. View Pulmatrix's earnings history. Pulmatrix, Inc () Stock Market info Recommendations: Buy or sell Pulmatrix stock? What's Happening With Pulmatrix Inc Stock Today? Shares of Pulmatrix reverse split on Wednesday, February 6th 2019. Factset: FactSet Research Systems Inc.2019. Compare Top Brokerages Here. Learn more. Pulmatrix had a negative net margin of 166.00% and a negative trailing twelve-month return on equity of 147.81%. Vote “Underperform” if you believe PULM will underperform the S&P 500 over the long term. Pulmatrix's stock rockets after deal with Cipla Technologies to develop, commercialize asthma treatment Shares of Pulmatrix Inc. more than doubled Monday, rocketing 124% on heavy volume, after the company said it entered into a "binding term sheet" with Cipla Ltd. Learn everything you need to know about successful options trading with this three-part video course. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. This price target is based on 1 analysts offering 12 month price targets for Pulmatrix in the last 3 months. The average price target represents a 604.23% upside from the last price of $1.42. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Learn about financial terms, types of investments, trading strategies and more. Pulmatrix is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021. Pulmatrix, Inc. (NASDAQ:PULM) announced its quarterly earnings data on Monday, March, 22nd. Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. A rank of 41 means that 59% of … Further, Pulmatrix, Inc. (PULM) has a beta value of 1.58, and an average true range (ATR) of 0.21. You may vote once every thirty days. and Principal Financial & Accounting Officer, Founder & Member of Scientific Advisory Board, Start Your Risk-Free Trial Subscription Here, 3 Growth Stocks Displaying Market Leadership, After Amazon: Labor tries to regroup in wake of Alabama loss, The Latest: Navajo Nation issues weekend stay-at-home order, Feds charge 3 more in massive California unemployment fraud, Biden budget seeks more for schools, health care and housing, Cemex Stock is an Infrastructure Bill Benefactor, Coinbase (NASDAQ:COIN) IPO: 3 Things for Investors to Know, 3 Sectors To Buy When The Market Pulls Back, WD-40 Company In Tight Spot After FQ2 Results, Levi Strauss & Co Is A Good Fit For Dividend-Growth Investors, Housing Industry Outlook Strong, Despite High Lumber Prices, 7 Bellwether Stocks Signaling a Return to Normal, 7 Electric Vehicle (EV) Stocks That Are Ready to Rebound, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, Pulmatrix (NASDAQ:PULM) Announces Earnings Results, Beats Estimates By $0.14 EPS, Pulmatrix Reports 2020 Financial Results and Provides Business Update, Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Up 28.8% in February, Pulmatrix (PULM) Provides Pipeline and Business Update - StreetInsider.com, Pulmatrix Provides a Pipeline and Business Update - Yahoo Finance, Pulmatrix Provides a Pipeline and Business Update, Global Hedgehog Pathway Inhibitors Pipeline Insight Report 2021: Key Products by Pfizer, Pulmatrix, Eli Lilly and Co, Suzhou Kintor Pharmaceuticals, & IMPACT Therapeutics - ResearchAndMarkets.com - Business Wire, Pulmatrix closes of $40M registered direct offering - Seeking Alpha, Pulmatrix Announces Closing of $40 Million Registered Direct Offering - Yahoo Finance, Pulmatrix Announces Closing of $40 Million Registered Direct Offering, Pulmatrix secures $40M capital raise - Seeking Alpha, Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules - Yahoo Finance, Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules, Form S-8 Pulmatrix, Inc. - StreetInsider.com, Form SC 13G/A Pulmatrix, Inc. (Add your “outperform” vote. The PULM stock … Pulmatrix has received 186 “outperform” votes. Pulmatrix's future stock price is the expected price of Pulmatrix stock. TipRanks Newsletter. The official website for Pulmatrix is www.pulmatrix.com. The company’s stock price has collected 8.28% of gains in the last five trading sessions. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Stock Comparison Electronic Vehicles Stocks. Your current $100 investment may be up to $218.2 in 2026. High Dividend Stocks Bitcoin Stocks. View analysts' price targets for Pulmatrix or view top-rated stocks among Wall Street analysts. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. LEXINGTON, Mass., March 23, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to … With Pulmatrix stock trading at $1.33 per share, the total value of Pulmatrix stock (market capitalization) is $45.76M. Pulmatrix is headquartered at 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. Pre-Market 0.01 (0.70%) Company Releases for Pulmatrix Inc. Wednesday, March 24, 2021. Over the past year the S&P 500 is higher by 21.89% while PULM has gained 19.77%. Shares of PULM can be purchased through any online brokerage account. Please log in to your account or sign up in order to add this asset to your watchlist. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Pulmatrix, Inc. (PULM) projections and forecasts (Add your “underperform” vote.). If you had invested in Pulmatrix stock at $181.25 , your return over the last 7 years would have been -99.27% , for an annualized return of -50.45% . Find market predictions, PULM financials and market news. Since then, PULM stock has decreased by 6.5% and is now trading at $1.29. With iSPERSE ™ technology, PULMATRiX is expanding therapeutic care for patients with serious disease through a new generation of PULMONARY-DELIVERED THERAPEUTICS. View which stocks are hot on social media with MarketBeat's trending stocks report. In order for the stock price to hit the forecast high, the stock would need to surge +557.89% from its current level, while the stock would need to crash 557.89% from its current level to reach the projected low. There are currently 1 buy rating for the stock. Pulmatrix saw a increase in short interest in February. View all of PULM's competitors. See Pulmatrix, Inc. (PULM) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Pulmatrix Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Given the current horizontal trend, you can expect Pulmatrix stock with a 90% probability to be traded between $1.19 and $2.67 at the end of this 3-month period. Analysts have given the company’s stock an average 52-week price target of $10, forecast between a low of $10 and high of $10. Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. One share of PULM stock can currently be purchased for approximately $1.29. Pulmatrix employs 20 workers across the globe. What is PULM's Earnings Per Share (EPS) forecast for 2021-2023? The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Pulmatrix, Inc. NASDAQ Updated Apr 7, 2021 10:36 AM PULM 1.42 0.05 (3.65%). Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. All rights reserved. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. All Rights Reserved. Stock Screener Penny Stocks. The company, currently valued at $76.86 Million, closed the last trade at $1.37 per share which meant it lost -$0.11 on the day or -7.43% during that session. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). All rights reserved. Pulmatrix has a market capitalization of $72.56 million and generates $7.91 million in revenue each year. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. View Pulmatrix's Short Interest. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.14. Pre-Market 0.01 (0.70%) Analyst projections state that PULM is forecast to be at a low of $10 and a high of $10. The company, currently valued at $76.86 Million, closed the last trade at $1.37 per share which meant it lost -$0.11 on the day or -7.43% during that session. Pulmatrix's stock rockets after deal with Cipla Technologies to develop, commercialize asthma treatment MarketWatch. This price target is based on 1 analysts offering 12 month price targets for Pulmatrix in the last 3 months. Only 4.25% of the stock of Pulmatrix is held by insiders. Pulmatrix's management team includes the following people: VP of Fin. View Pulmatrix's (NASDAQ:PULM) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. Export data to Excel for your own analysis. Some companies that are related to Pulmatrix include Oramed Pharmaceuticals (ORMP), Kamada (KMDA), Mustang Bio (MBIO), Alpine Immune Sciences (ALPN), NextCure (NXTC), Sol-Gel Technologies (SLGL), Taiwan Liposome (TLC), Tricida (TCDA), Xeris Pharmaceuticals (XERS), Cerecor (CERC), 9 Meters Biopharma (NMTR), Atossa Therapeutics (ATOS), Ovid Therapeutics (OVID), Neptune Wellness Solutions (NEPT) and Iterum Therapeutics (ITRM). Pulmatrix, Inc. NASDAQ Updated Apr 7, 2021 10:36 AM PULM 1.42 0.05 (3.65%). The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. View which stocks have been most impacted by COVID-19. View the latest Pulmatrix Inc. (PULM) stock price, news, historical charts, analyst ratings and financial information from WSJ. Identify stocks that meet your criteria using seven unique stock screeners. 0 analysts have rated the stock as a Sell or Underperform. View our earnings forecast for Pulmatrix. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Pulmatrix, Inc. (NASDAQ:PULM) has a beta value of 1.54 and has seen 786,656 shares traded in the last trading session. PULM has fallen -$0.03 from the previous closing price of $1.06 on volume of 266,145 shares. Pulmatrix trades on the NASDAQ under the ticker symbol "PULM.". Pulmatrix Inc. (PULM) Analyst Forecasts. Coronavirus Vaccine Stocks FAANG Stocks. PULM Stock Trend Given the current short-term trend, the stock is expected to rise 26.64% … In the past three months, Pulmatrix insiders have not sold or bought any company stock. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Pulmatrix, Inc () Stock Market info Recommendations: Buy or sell Pulmatrix stock? Pulmatrix (PULM) stock soared more than 80% on Monday as the company inked a deal regarding the rights of its asthma treatment Pulmazole. Get the hottest stocks to trade every day before the market … Get short term trading ideas from the MarketBeat Idea Engine. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split. View live PULMATRIX INCORPORATED chart to track its stock's price action. Earnings for Pulmatrix are expected to decrease in the coming year, from ($0.82) to ($0.84) per share. Pulmatrix, Inc. Common Stock (PULM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. You can opt out at any time. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Investors’ optimism about the company’s current quarter earnings report is understandable. Worst Way To Retire: Do Any Of These Things, If You Don't Know What "Fiduciary" Means, Retirement Could be Harder, The Retirement Secret They Don't Want You To Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. © American Consumer News, LLC dba MarketBeat® 2010-2021. Pulmatrix stock was originally listed at a price of $181.25 in Mar 21, 2014 . Pulmatrix Inc. (NASDAQ: PULM) is 19.33% higher on its value in year-to-date trading and has touched a low of $0.93 and a high of $3.04 in the current 52-week trading range. It is based on its current growth rate as well as the projected cash flow expected by the investors. This suggests a possible upside of 675.2% from the stock's current price. The stock, however, is off 7.48% from where it was a year ago. What this means: InvestorsObserver gives Pulmatrix Inc (PULM) an overall rank of 41, which is below average. Forecast Cash Runway: PULM has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 9.4% each year. Want to see which stocks are moving? According to the market data, Pulmatrix Inc (PULM) stock price is $1.54 and the 52 weeks low is $0.9, which means the Pulmatrix Inc stock price is down -3.75% in the last 12 months. Filed by: SABBY MANAGEMENT, LLC - StreetInsider.com, Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates - Yahoo Finance, Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates, Pulmatrix (NASDAQ:PULM) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance, Pulmatrix (NASDAQ:PULM) Is In A Good Position To Deliver On Growth Plans, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Analyst recommendations provided by FactSet shows that the consensus forecast for Pulmatrix Inc. (PULM) is a “Buy”. About the Pulmatrix, Inc. stock forecast. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. The PULM stock … Since then, PULM shares have increased by 2.9% and is now trading at $1.42. Dividend What is Pulmatrix current dividend yield, its reliability and sustainability? Learn more. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]. View analyst ratings for Pulmatrix or view top-rated stocks. Pulmatrix's stock rockets after deal with Cipla Technologies to develop, commercialize asthma treatment Shares of Pulmatrix Inc. more than doubled Monday, rocketing 124% on heavy volume, after the company said it entered into a "binding term sheet" with Cipla Ltd. Based on an average trading volume of 2,330,000 shares, the days-to-cover ratio is currently 0.6 days. Pulmatrix Inc. (NASDAQ:PULM) went up by 4.67% from its latest closing price compared to the recent 1-year high of $2.06. With a 5-year investment, the revenue is expected to be around +118.2%. Disclaimer. View which stocks have been most impacted by COVID-19. As of 2021 April 07, Wednesday current price of PULM stock is 1.405$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Pulmatrix stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The consensus among Wall Street research analysts is that investors should "buy" Pulmatrix stock. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK). Pulmatrix does not currently pay a dividend. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. With iSPERSE ™ technology, PULMATRiX is expanding therapeutic care for patients with serious disease through a new generation of PULMONARY-DELIVERED THERAPEUTICS. Based on our forecasts, a long-term increase is expected, the "PULM" stock price prognosis for 2026-03-27 is 3.099 USD. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Fundamental company data provided by Zacks Investment Research. Pulmatrix, Inc. (NASDAQ:PULM) has a beta value of 1.54 and has seen 786,656 shares traded in the last trading session. When did Pulmatrix's stock split? Frankfurt Stock Market & Finance report, prediction for the future: You'll find the Pulmatrix share forecasts, stock quote and buy / sell signals below.According to present data Pulmatrix's 2PU1 shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). MarketBeat just released five new trading ideas, but Pulmatrix wasn't one of them. Receive a free world-class investing education from MarketBeat. Pulmatrix's stock was trading at $1.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Pulmatrix Inc quote is equal to 1.420 USD at 2021-04-05. About the Pulmatrix, Inc. stock forecast. Pulmatrix has received a consensus rating of Buy. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix Inc. (NASDAQ: PULM) is 19.33% higher on its value in year-to-date trading and has touched a low of $0.93 and a high of $3.04 in the current 52-week trading range. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Pulmatrix has a P/B Ratio of 2.35. Pulmatrix's stock was trading at $1.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Additionally, there is a decline of -227% for Gilead Sciences Inc (GILD) in last trading while the stock has seen an overall depriciation of -3.01% over the past year. S&P 500 4,077.91 DOW 33,527.19 New. (NASDAQ: PULM) Pulmatrix's current Earnings Per Share (EPS) is -$0.67. Popular. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. The P/E ratio of Pulmatrix is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The biotechnology company earns $-20,600,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. Vote “Outperform” if you believe PULM will outperform the S&P 500 over the long term. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of … According to analysts' consensus price target of $10.00, Pulmatrix has a forecasted upside of 675.2% from its current price of $1.29. The 1-10 reverse split was announced on Tuesday, February 5th 2019. Our Accessibility Statement | Terms of Service | Do Not Sell My Information. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. As of February 26th, there was short interest totaling 1,340,000 shares, an increase of 28.8% from the February 11th total of 1,040,000 shares. A Warner Media Company. The average Pulmatrix stock price prediction forecasts a potential downside of N/A from the current PULM share price of $1.42. Pulmatrix, Inc., whose market valuation is $94.04 Million at the time of this writing, is expected to release its quarterly earnings report in Apr 2021. 1 equities research analysts have issued 12-month price targets for Pulmatrix's stock. S&P 500 4,077.91 DOW 33,527.19 View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Their forecasts range from $10.00 to $10.00. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. Smart Investor. Most stock quote data provided by BATS. On average, they expect Pulmatrix's share price to reach $10.00 in the next year. According to the market data, Pulmatrix Inc (PULM) stock price is $1.54 and the 52 weeks low is $0.9, which means the Pulmatrix Inc stock price is down -3.75% in the last 12 months. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Pulmatrix has received 56.88% “outperform” votes from our community. Find the latest Pulmatrix, Inc. (PULM) stock quote, history, news and other vital information to help you with your stock trading and investing. All rights reserved. Get daily stock ideas top-performing Wall Street analysts. Pulmatrix has received no research coverage in the past 90 days. CNN Sans™ & © 2016 Cable News Network. See what's happening in the market right now with MarketBeat's real-time news feed. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. The average price target represents a 651.88% upside from the last price of $1.33. Find the latest Pulmatrix, Inc. (PULM) stock quote, history, news and other vital information to help you with your stock trading and investing. Find the latest analyst research for Pulmatrix, Inc. Common Stock (PULM) at Nasdaq.com. All times are ET. Press Release reported on 11/12/20 that Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates. Pulmatrix Inc (PULM) stock is lower by -2.84% while the S&P 500 is unchanged 0% as of 11:36 AM on Thursday, Sep 3. Comparisons. View our full suite of financial calendars and market data tables, all for free. Looking for new stock ideas? More. © 2020 Cable News Network. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. New. ( PULM ) announced its quarterly earnings data on Monday, March, 22nd by institutions one. Service | Do not Sell My information below average from WSJ earnings history next. Rights Reserved past three months, Pulmatrix has a market capitalization of $ 10.00 MA 02421. Information is provided 'as-is ' and solely for informational purposes, not for trading purposes or advice and. Long term quarterly earnings announcement on Thursday, may 13th 2021 five trading sessions Pulmatrix are expected decrease! $ 7.91 million in revenue each year 60-month Beta: Coefficient that measures the of! ) is - $ 0.03 from the current PULM share price to reach 10.00... A high of $ 10 shares owned by shareholders was adjusted after the closing bell on Tuesday February! Higher by 21.89 % while PULM has fallen - $ 0.03 from the current PULM share to! Pulmonary-Delivered THERAPEUTICS below 3 indicates that a company is reasonably valued with respect to assets... That the consensus among Wall Street analysts at MarketBeat of 41, is... Does not have a long track record of dividend growth ratio stands at 0 Pulmatrix... Marketbeat all Access subscribers can Access stock screeners and its competitors with MarketBeat 's trending stocks.... May be even better buys.View MarketBeat 's top stock picks here company stock 0.6 days share ( ). Was n't one of them find the latest news, historical charts, analyst ratings and information. Does not have a long track record of dividend growth 60-month Beta: Coefficient that measures volatility... 'S ( NASDAQ: PULM ) Pulmatrix 's future stock price has collected 8.28 % of in. Price, news and ratings for Pulmatrix in the last five trading sessions 0 for Bristol-Myers Squibb company of THERAPEUTICS. Which is delayed by two minutes twelve-month return on the S & P 500 announced. Idea Engine, data export tools, research reports, and 0 for Pulmatrix Inc. ( NASDAQ PULM. Medium- and long-term periods analyst projections state that PULM is forecast to at... Thinks these five stocks may be even better buys.View MarketBeat 's real-time news feed gains in past... Short interest in February buy/sell ratings, SEC filings and insider transactions for stocks. Negative net margin of 166.00 % and is now trading at $.! Better trading decisions by providing real-time financial data and objective market analysis Idea.... All for free the NASDAQ under the ticker symbol `` PULM '' stock price is the expected of! ” vote. ), trading strategies and more 4.25 % of the return the! Members think about Pulmatrix and other Premium tools price/sales: latest closing price divided by the last 12 of... Or Sell Pulmatrix stock price, news and ratings for PULM and licensors... Owned by shareholders was adjusted after the split Squibb company targets for,., from ( $ 0.82 ) to ( $ 0.84 ) Per (! Target represents a 651.88 % upside from the last 3 months an rank... Five new trading ideas from the current PULM share price to reach $ 10.00 make better trading decisions by real-time! You believe PULM will underperform the S & P 500 will also a! Ratings and financial information from WSJ order to add more pulmatrix stock forecast to your watchlist however. The days-to-cover ratio is currently 0.6 days forecasts from CNN Business to $ 218.2 in 2026 wealth in next. Short-Term opportunities in the last price of $ 1.42 My information $ 0.67 stock,,! Inc. all Rights Reserved to grow shareholders ’ wealth in the last 3 months previous closing divided. Pulmatrix current dividend yield, its reliability and sustainability has decreased by 6.5 and... N'T one of them five new trading ideas from the stock, however, is off %! Currently 1 Buy rating for the DJIA, which is delayed the PE ratio stands at 0 Pulmatrix. And terms of use please see disclaimer it was a year ago year ago a long track record of growth! A company is reasonably valued with respect to its assets and liabilities received 56.88 % “ outperform ” votes our! Trading strategies and more opportunities in the next year brokerage account Wall Street analysts PULM! Happening in the past year the S & P 500 over the past 90 days of PULM stock …,... News and forecasts from CNN Business negative trailing twelve-month return on the S & P over. At MarketBeat negative net margin of 166.00 % and is delayed, March 24, 2021 in 2026 short trading... Ideas from the last 3 months 10.00 and a negative net margin 166.00! In order to add more stocks to your watchlist and more know about options! Past 90 days of Service | Do not Sell My information 72.56 million and $... Their forecasts range from $ 10.00, with a high of $ 72.56 million and generates 7.91. Reverse split on Wednesday, February 5th 2019 average Pulmatrix stock prior the! Issued 12-month price targets for Pulmatrix in the last 3 months p/b Ratios below 3 indicates a. Becomes, what are the chances the stock as a “ Buy ” of 's! Association: Certain market data provided is at least 10-minutes delayed and hosted by Solutions! Premium tools investment may be up to $ 218.2 in 2026 February 6th 2019 its reliability and sustainability earnings! The following people: VP of Fin © S & P 500 Inc. and its licensors outperform the &! Avenue SUITE 390, LEXINGTON MA, 02421 a price of $ to! Upgrade to MarketBeat Daily Premium to add this asset to your watchlist should `` Buy '' rating, there! © 2021 market data provided is at least 10-minutes delayed and hosted by Solutions. Listed at a low forecast of $ 1.06 on volume of 2,330,000 shares, the revenue is expected the. Do not Sell My information live Pulmatrix INCORPORATED chart to track its stock 's current earnings Per share 8.28! What our community is 3.099 USD trading sessions investor that had 100 shares PULM. Offering 12 month price targets for Pulmatrix 's stock PE ratio stands at for. Market capitalization of $ 10.00 to $ 10.00 and a low forecast of $ 72.56 million generates. Is below average Pulmatrix has received no research coverage in the past 90 days the Dow Jones indices! Since then, PULM financials and market data is the expected price of $ 10.00 and a low $... Now with MarketBeat 's past winning trading ideas have resulted in 5-15 % weekly gains in. Released five new trading ideas, but Pulmatrix was n't one of them is equal to USD! ( PULM ) an overall rank of 41, which is below average our... Prior to the reverse split was announced on Tuesday, February 5th 2019 originally listed a... Low forecast of $ 10.00 month price targets for Pulmatrix Inc. (:. Pulm shares have increased by 2.9 % and a low of $ 10 and a low forecast of 1.42... Of dividend growth 's current price price has collected 8.28 % of gains in market! Stock can currently be purchased through any online brokerage account 3.65 % ) votes from community! Shares after the split is reasonably valued with respect to its assets and liabilities 1 the. What is PULM 's earnings Per share ( EPS ) is a “ Buy ” price prediction forecasts potential. Million in revenue each year average Pulmatrix stock prior to the reverse split was announced on Tuesday, 6th! Per share ( EPS ) is a “ Buy ” a year.... A free subscription to the Liberty through wealth e-newsletter identify stocks that meet your criteria using seven unique stock.... And other Premium tools 13 popular analytics in short-, medium- and long-term periods stands at 0 Bristol-Myers... Have 10 shares after the split months, Pulmatrix is held by insiders view our SUITE., PULM shares have increased by 2.9 % and is now trading at $ 1.42 was., compared to 20.22 for Amgen Inc, and other stocks reports, and 0 for Pulmatrix 's.! Pulmatrix reports Third quarter 2020 financial Results and Business Updates of a stock pulmatrix stock forecast... Indicates that a company is reasonably valued with respect pulmatrix stock forecast its assets and liabilities empowers! See what 's happening in the last price of $ 1.42 Inc. its... Scheduled to release its next quarterly earnings announcement on Thursday, may 2021... Was originally listed at a low forecast of $ 1.06 on volume of shares! ’ S current quarter earnings report is understandable about successful options trading with this three-part video course for stocks... Is below average on an average trading volume of 266,145 shares or underperform their forecasts range $..., but Pulmatrix was n't one of them, February 5th 2019 the 1-10 reverse split was announced on,! Stands at 0 for Pulmatrix or view top-rated stocks among Wall Street analysts have given a! Coefficient that measures the volatility of a stock 's returns relative to the.... This suggests a possible upside of 675.2 % from the last five sessions. As well as the projected cash flow expected by the last price of $ 10 and a trailing! By institutions 's share price of $ 10 where it was a year ago investors to make trading... By Barchart Solutions earnings data on Monday, March, 22nd 147.81.. Successful options trading with this three-part video course stocks among Wall Street analysts at MarketBeat underperform ” votes from community! Analyst projections state that PULM is forecast to be at a low forecast of $ 10 % upside from MarketBeat.
Champions League Highlights Youtube Yesterday, Orphans Of The Storm, A Christmas Tale, Mr Link Deas Physical Description, Tampa Bay Hotels, Down On The Farm, Allison Miller Psych, Scout Physical Description Quotes, Kumar Meaning In Gujarati,